摘要
目的探讨Smad7和IL-6在原发性肝细胞癌中的表达及临床意义。方法收集56例肝细胞癌患者术后肝癌组织及癌旁肝硬化组织,采用荧光定量PCR检测Smad7转录情况,免疫组化方法检测Smad7蛋白的表达水平,对比Smad7表达与患者一般临床病理特征如年龄、性别、肿瘤大小、肿瘤计数、组织病理分化、TNM分期、是否存在包膜、门静脉系统侵犯、血清甲胎蛋白(AFP)浓度以及血清HBs Ag阳性率的关系。术前采用ELISA法检测肝癌患者血清中IL-6表达水平,与36位健康体检者血清IL-6水平对比。结果肝癌组织中Smad7转录水平低于对应癌旁肝硬化组织,肝癌组织中Smad7蛋白阳性表达率均低于癌旁肝硬化组织(P<0.05)。肝癌组织Smad7阳性表达组与阴性表达组在肿瘤大小、组织病理分化、TNM分期、门静脉系统侵犯方面比较,差异有统计学意义(P<0.05);肝癌组血清中IL-6水平高于健康组(P<0.05)。结论原发性肝细胞癌中存在Smad7和IL-6的异常表达,Smad7和IL-6可能是评估患者病情新的生物标志物。
Objective To investigate the expression of Smad7 and IL - 6 in primary hepatocellular carcinoma and its clinical significance. Methods The hepatocellular carcinoma tissues and adjacent liver cirrhosis tissues of 56 patients with hepatocellular carcinoma were cullected. The transcription level of Smad7 was detected by real - time PCR, and the expression of Smad7 protein was detected by immunohistochemical method. The relationship between expression of Smad7 and the general clinicopath- ologieal features such as age, sex, tumor size, tumor eount, histopathological differentiation, TNM staging, presence of envelope, portal vein system invasion, serum alpha -fetoprotein （AFP） concentration and serum HBsAg were analyzed. Preoperative ELISA method was used to detect the expression of IL - 6 in serum of patients with hepatocellular caIv：inoma, and compared with the level of serum IL -6 in 36 healthy subjects. Results The expression of Smad7 protein in hepatoceilulat＂ car（＇inoma tissues was lower than that in adjacent liver cirrhosis tissues, and the pusitive expression rate of Smad7 protein in hepatocellular carcinoma tissues was lower than that in adjacent liver cirrhosis tissues （ P 〈 0. 05 ）. The level of IL - 6 in hepatoce-ellular carcinuma group was higher than that in healthy group （P 〈 0. 05）. The level of IL- 6 in hepatocellular carcinoma group was significantly higher than that in healthy group （ P 〈 0. 05 ）, and the dilterence was statistically significant （ P 〈 0. 05 ）. Conclusion The ex- pression of Smad7 and IL - 6 was abnormal in hepatocellular carcinoma. Smad7 and IL - 6 may be the new biomarkers tu evaluate the condition of patients.
出处
《河南医学研究》
CAS
2017年第21期3866-3869,共4页
Henan Medical Research
